Dynamic-Electro Enhanced Chemotherapy brings relief to palliative patients with large tumour burden
Gurusamy, Kalavathy ; Gurumurthy,, G. ; Kar, Rajesh ; Saravanan ; Mathew, Asake and Persson, Bertil R LU
(2018)
In Trends in Cancer Research
13.
p.29-41
- Abstract
- The aim of the present work is to perform a clinical case study evaluating the concept of Dynamic-ElectroEnhanced Chemotherapy™ (D-EECT). Ten patients with squamous cell carcinoma, eight with breast cancer and five patients with each presenting a different type of tumour, were entered in the trials initiated by five different cancer centres. All the patients were given Bleomycin and 2 to 3 treatment sessions with IQWave™ (Scandinavian ChemoTech AB. Sweden) according to the D-EECT protocol, which starts with pulses of amplitude 1000 V that successively reduces to about 400 V with an electrode distance of 12 mm. An average complete response of 26% and an average partial response of 74% add up to 100% objective response for all treated... (More)
- The aim of the present work is to perform a clinical case study evaluating the concept of Dynamic-ElectroEnhanced Chemotherapy™ (D-EECT). Ten patients with squamous cell carcinoma, eight with breast cancer and five patients with each presenting a different type of tumour, were entered in the trials initiated by five different cancer centres. All the patients were given Bleomycin and 2 to 3 treatment sessions with IQWave™ (Scandinavian ChemoTech AB. Sweden) according to the D-EECT protocol, which starts with pulses of amplitude 1000 V that successively reduces to about 400 V with an electrode distance of 12 mm. An average complete response of 26% and an average partial response of 74% add up to 100% objective response for all treated tumours. A new quantity “weighted response" WR = (3 x CR + PR - 3 x PD)/3 was introduced, that considers the cases of progressive disease (PD) as well. For the 10 cases of squamous cell carcinoma in the present study the weighted response was 47%. Considering squamous cell carcinoma (SCC) tumours larger than 3 cm the weighted response of 47% in the present study is about twice the WR of 23% for SCC tumours > 3 cm treated according to the European Standard operating procedures (ESOPE) protocol. The WR results of breast cancer. 43-67%. in the present study are almost equal to the WR averages of 47- 80% in treatment of breast cancer nodules of different sizes according to the ESOPE protocol. The WR result of 67% for patients with breast- infiltrated ductal carcinoma with large. 10-15 cm. tumours is however, better than the WR of 47% for tumours larger than 3 cm in breast cancer patients treated according to the ESOPE protocol. In clinical studies of various types of tumours treated according to the ESOPE protocol an average of about 5% progressive disease was recorded, whereas no cases of progressive disease were recorded in the present study. (Less)
- Abstract (Swedish)
- Syftet med nuvarande arbetet är att genomföra en klinisk fallstudie som utvärderar begreppet Dynamisk-ElectroEnhanced Chemotherapy ™ (D-EECT). Tio patienter med plavocellkarcinom, åtta med bröstcancer och fem patienter med var och en som presenterade en annan typ av tumör, infördes i försöken initierade av fem olika cancercentra. Alla patienter fick Bleomycin och 2-3 behandlingstider med IQWave ™ (Scandinavian ChemoTech AB) enligt D-EECT-protokollet, som börjar med pulser med amplitud 1000 V som successivt minskar till ca 400 V med ett elektrodavstånd av 12 mm. Ett genomsnittligt komplett svar på 26% och ett genomsnittligt partiellt svar på 74% bidrar till 100% objektivt svar för alla behandlade tumörer. En ny kvantitet "vägt svar" WR = (3... (More)
- Syftet med nuvarande arbetet är att genomföra en klinisk fallstudie som utvärderar begreppet Dynamisk-ElectroEnhanced Chemotherapy ™ (D-EECT). Tio patienter med plavocellkarcinom, åtta med bröstcancer och fem patienter med var och en som presenterade en annan typ av tumör, infördes i försöken initierade av fem olika cancercentra. Alla patienter fick Bleomycin och 2-3 behandlingstider med IQWave ™ (Scandinavian ChemoTech AB) enligt D-EECT-protokollet, som börjar med pulser med amplitud 1000 V som successivt minskar till ca 400 V med ett elektrodavstånd av 12 mm. Ett genomsnittligt komplett svar på 26% och ett genomsnittligt partiellt svar på 74% bidrar till 100% objektivt svar för alla behandlade tumörer. En ny kvantitet "vägt svar" WR = (3 x CR + PR - 3 x PD) / 3 introducerades, vilket även omfattar fall av progressiv sjukdom (PD). För de 10 fallen av skivkörtelcancer i föreliggande studie Det vägda svaret var 47%. Med tanke på tumörer i skivkroppscancer (SCC) större än 3 cm är det viktiga svaret på 47% i den aktuella studien ungefär dubbelt så mycket som WR på tumörer> 3 cm som behandlas enligt European Standard procedurer (ESOPE) protokollet. WR-resultaten av bröstcancer, 43-67%. I den föreliggande studien är nästan lika med WR-medlen på 47-80% vid behandling av bröstcancer-noduler av olika storlekar enligt ESOPE-protokollet. WR-resultat av 67% för patienter med bröstinfiltrerat duktalt karcinom med stora 10-15 cm tumörer är dock bättre än WR-roten på 47% för tumörer större än 3 cm hos bröstcancerpatienter behandlade enligt ESOPE-protokollet. kliniska studier av olika typer av tumörer behandlade enligt ESOPE-protokollet registrerades ett genomsnitt på ca 5% progressiv sjukdom, medan inga fall av progressiv sjukdom registrerades i föreliggande studie (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/90c157bb-f125-43e6-9fc0-8580fba2cad2
- author
- Gurusamy, Kalavathy
; Gurumurthy,, G.
; Kar, Rajesh
; Saravanan
; Mathew, Asake
and Persson, Bertil R
LU
- organization
- alternative title
- Dynamisk-Electro Färstärkt Kemotherapy ger lindring till palliativa patienter med stor tumörbörda
- publishing date
- 2018-09-08
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Dynamic-ElectroEnhanced Chemotherapy, D-EECT, squamous cell carcinoma, breast cancer, IQWave, objective response, complete response, partial response, weighted response, ESOPE, Dynamic-ElectroEnhanced Chemotherapy, D-EECT, squamous cell carcinoma, breast cancer, IQWave, objective response, complete response, partial response, weighted responseweighted response, ESOPE
- in
- Trends in Cancer Research
- volume
- 13
- pages
- 12 pages
- publisher
- Research Trends, Trivandium
- ISSN
- 0973-1040
- language
- English
- LU publication?
- yes
- additional info
- http://www.researchtrends.net/tia/title_issue.asp?id=57&in=0&vn=13&type=3
- id
- 90c157bb-f125-43e6-9fc0-8580fba2cad2
- alternative location
- http://www.researchtrends.net/tia/title_issue.asp?id=57&in=0&vn=13&type=3
- date added to LUP
- 2019-05-05 12:43:31
- date last changed
- 2022-04-05 10:41:00
@article{90c157bb-f125-43e6-9fc0-8580fba2cad2,
abstract = {{The aim of the present work is to perform a clinical case study evaluating the concept of Dynamic-ElectroEnhanced Chemotherapy™ (D-EECT). Ten patients with squamous cell carcinoma, eight with breast cancer and five patients with each presenting a different type of tumour, were entered in the trials initiated by five different cancer centres. All the patients were given Bleomycin and 2 to 3 treatment sessions with IQWave™ (Scandinavian ChemoTech AB. Sweden) according to the D-EECT protocol, which starts with pulses of amplitude 1000 V that successively reduces to about 400 V with an electrode distance of 12 mm. An average complete response of 26% and an average partial response of 74% add up to 100% objective response for all treated tumours. A new quantity “weighted response" WR = (3 x CR + PR - 3 x PD)/3 was introduced, that considers the cases of progressive disease (PD) as well. For the 10 cases of squamous cell carcinoma in the present study the weighted response was 47%. Considering squamous cell carcinoma (SCC) tumours larger than 3 cm the weighted response of 47% in the present study is about twice the WR of 23% for SCC tumours > 3 cm treated according to the European Standard operating procedures (ESOPE) protocol. The WR results of breast cancer. 43-67%. in the present study are almost equal to the WR averages of 47- 80% in treatment of breast cancer nodules of different sizes according to the ESOPE protocol. The WR result of 67% for patients with breast- infiltrated ductal carcinoma with large. 10-15 cm. tumours is however, better than the WR of 47% for tumours larger than 3 cm in breast cancer patients treated according to the ESOPE protocol. In clinical studies of various types of tumours treated according to the ESOPE protocol an average of about 5% progressive disease was recorded, whereas no cases of progressive disease were recorded in the present study.}},
author = {{Gurusamy, Kalavathy and Gurumurthy,, G. and Kar, Rajesh and Saravanan and Mathew, Asake and Persson, Bertil R}},
issn = {{0973-1040}},
keywords = {{Dynamic-ElectroEnhanced Chemotherapy; D-EECT; squamous cell carcinoma; breast cancer; IQWave; objective response; complete response; partial response; weighted response; ESOPE; Dynamic-ElectroEnhanced Chemotherapy; D-EECT; squamous cell carcinoma; breast cancer; IQWave; objective response; complete response; partial response; weighted responseweighted response; ESOPE}},
language = {{eng}},
month = {{09}},
pages = {{29--41}},
publisher = {{Research Trends, Trivandium}},
series = {{Trends in Cancer Research}},
title = {{Dynamic-Electro Enhanced Chemotherapy brings relief to palliative patients with large tumour burden}},
url = {{https://lup.lub.lu.se/search/files/63790684/CNR_147_Vol_13_29_41.pdf}},
volume = {{13}},
year = {{2018}},
}